Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019.
Food and Drug Administration's Adverse Event Reporting Systems
adalimumab
coronavirus disease 2019
delayed cutaneous hypersensitivity reactions
infliximab
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
03
01
2023
received:
13
12
2022
accepted:
11
01
2023
pubmed:
27
1
2023
medline:
3
3
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Recent evidence has emerged concerning delayed cutaneous hypersensitivity reactions after infliximab or adalimumab applications in patients with coronavirus disease 2019 (COVID-19). A few real-world studies compared the events, clinical features, and prognosis of infliximab- or adalimumab-related delayed cutaneous hypersensitivity reactions in COVID-19 patients. Disproportionality analysis and Bayesian analysis were utilized to determine the suspected adverse events of delayed cutaneous hypersensitivity reactions after infliximab or adalimumab use based on the Food and Drug Administration's Adverse Event Reporting Systems (FAERS) from May 2020 to December 2021. Additionally, the times to onset and fatality rates of delayed cutaneous hypersensitivity reactions following infliximab or adalimumab were compared. In total, 475 reports of delayed cutaneous hypersensitivity reactions were associated with infliximab or adalimumab. Females were affected almost twice more than males. Among the two therapies, infliximab had the highest association with delayed cutaneous hypersensitivity reactions based on the highest reporting odds ratio (2.14, 95% two-sided confidence interval [CI] = 1.2-3.81), proportional reporting ratio (1.95, χ
Identifiants
pubmed: 36700393
doi: 10.1002/jmv.28518
pmc: PMC10107992
doi:
Substances chimiques
Adalimumab
FYS6T7F842
Infliximab
B72HH48FLU
Antibodies, Monoclonal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28518Informations de copyright
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Cochrane Database Syst Rev. 2022 Jun 13;6:CD015209
pubmed: 35695334
Expert Opin Drug Saf. 2016 Jan;15(1):43-52
pubmed: 26559805
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e299-e300
pubmed: 32314436
MMWR Morb Mortal Wkly Rep. 2004 Aug 6;53(30):683-6
pubmed: 15295313
Aliment Pharmacol Ther. 2009 May 1;29(9):921-7
pubmed: 19210297
Nat Rev Rheumatol. 2017 Apr;13(4):217-233
pubmed: 28275260
Clin Microbiol Rev. 2020 Jun 24;33(4):
pubmed: 32580969
Gut. 2021 Mar;70(3):623-624
pubmed: 32554621
J Cutan Pathol. 2022 Jan;49(1):34-41
pubmed: 34292611
Mol Biol Rep. 2022 Mar;49(3):2303-2309
pubmed: 35076845
J Pediatr Gastroenterol Nutr. 2021 May 1;72(5):736-741
pubmed: 33416268
Dermatol Clin. 2021 Oct;39(4):653-673
pubmed: 34556254
Trends Cell Biol. 2016 Apr;26(4):249-261
pubmed: 26791157
Br J Dermatol. 2020 Jul;183(1):71-77
pubmed: 32348545
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Am J Clin Dermatol. 2017 Dec;18(6):771-787
pubmed: 28597181
Gut. 2021 Jul;70(7):1396-1405
pubmed: 33431575
Int Immunopharmacol. 2021 Oct;99:107961
pubmed: 34426106
J Med Virol. 2023 Feb;95(2):e28518
pubmed: 36700393
Arthritis Rheum. 2008 Jul 15;59(7):996-1001
pubmed: 18576309
J Exp Med. 2005 Jul 4;202(1):135-43
pubmed: 15998792
Methods. 2005 May;36(1):3-10
pubmed: 15848070
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926800
pubmed: 32436460
Ann Oncol. 2005 Sep;16(9):1425-33
pubmed: 16012181
Lancet. 2020 May 2;395(10234):1407-1409
pubmed: 32278362
Med Drug Discov. 2020 Sep;7:100052
pubmed: 32537610
Lancet Respir Med. 2022 Mar;10(3):255-266
pubmed: 34922649
Pharmacol Ther. 2008 Feb;117(2):244-79
pubmed: 18155297
Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):705-715
pubmed: 34188251
JAMA. 2008 Oct 8;300(14):1639
pubmed: 18840827
JAMA Oncol. 2019 Apr 01;5(4):529-536
pubmed: 30605213
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2499-2504
pubmed: 32585074
J Am Acad Dermatol. 2020 Jul;83(1):e31
pubmed: 32283230
Open Forum Infect Dis. 2020 Jun 21;7(7):ofaa249
pubmed: 32661498
Trials. 2022 Sep 2;23(1):737
pubmed: 36056419
Gut. 2009 Apr;58(4):501-8
pubmed: 18832524
Clin Microbiol Rev. 2021 May 12;34(3):
pubmed: 33980688
Cell Biochem Funct. 2021 Jan;39(1):4-9
pubmed: 32803762